MAP2K7 and retinal disorder: Indeed, early cases show that other FGFR inhibitors, such as erdafitinib (Balversa®; Janssen Biotech) (1, 2), infigratinib (TruseltiqTM; Helsinn Healthcare) (1) and AZD4547 (3) lead to retinopathy similar to that caused by MEK inhibitors.